ADC Therapeutics SA — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADC Therapeutics SA filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.36M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $70.84M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $69.56M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $209.91M | Mar 13, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $69.06M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $74.91M | Mar 13, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($142.62M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($157.85M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($240.05M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($157.13M) | Mar 13, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.50M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($130.65M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($165.99M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($123.34M) | Mar 13, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $323.15M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $321.98M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $354.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $490.86M | Mar 13, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $508.98M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $524.62M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $503.03M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $411.41M | Mar 13, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($185.83M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($202.64M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($148.25M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $79.45M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $154.03M | Mar 13, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 13, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 13, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.34M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $250.87M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $278.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $326.44M | Mar 13, 2024 |